“…According to the current state of knowledge, interleukin-25 (IL-25), interleukin-33 (IL-33) and thymic stromal lymphopoietin (TSLP) are present in skin with an impaired barrier and are responsible for enhancing type 2 inflammation and the overproduction of Th2-profile interleukin-4 (IL-4) Table 3. Differences in preterm and term-born patients' skin, based on the studies of Saitoh et al [33], Visscher et al [31] and interleukin-13 (IL-13) [22,44]. Additionally, CCL (CC chemokine ligand), CCL17, CCL18, CCL22 and CCL26, chemokines related to IL-4 and IL-13, are also overexpressed in the affected skin in patients with AD [45].…”